Treatment of Chronic Constipation: Current Pharmacologic Approaches and Future Directions
Full Text Available
This article has an accompanying continuing medical education activity on page 496. Learning Objectives—Upon completion of this CME examination, successful learners will be able to identify the strength of evidence and mechanism of action of commonly used and future agents for the management of chronic constipation.
Conflicts of interest The authors disclose the following: Dr Tack is a consultant for Addex Pharma, AGI Therapeutics, Aryx, Astellas, AstraZeneca, Bayer, Chugai, Dainippon Sumimoto Pharma, GSK, Johnson & Johnson, Medtronic, Menarini, Movetis, Novartis, Nycomed, Ocera, Pfizer, Procter and Gamble, Rose Pharma, Smartpill, Solvay, Theravance, Tranzyme, and Zeria; Dr Müller-Lissner is a consultant for Boehringer International, Movetis, Mundipharma, and Procter & Gamble. Writing assistance was provided by Katherine Carpenter and Jude Douglass, and was funded by Movetis NV.
PII: S1542-3565(08)01229-9
doi:10.1016/j.cgh.2008.12.006
© 2009 AGA Institute. Published by Elsevier Inc. All rights reserved.
Refers to article:
- Exam 1: Treatment of Chronic Constipation: Current Pharmacological Approaches and Future Directions , 27 February 2009


